Hm Payson & CO Moderna, Inc. Transaction History

Hm Payson & CO

$5.49 Billion
Q2 2024

A detailed history of Hm Payson & CO transactions in Moderna, Inc. stock. As of the latest transaction made, Hm Payson & CO holds 151 shares of MRNA stock, worth $9,928. This represents 0.0% of its overall portfolio holdings.

Number of Shares

151

Previous 141 7.09%

Holding current value

$9,928

Previous $15,000 13.33%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$101.21 - $166.61 $1,012 - $1,666	10 Added 7.09%	151 $17,000
Q4 2023 Feb 13, 2024	SELL	$69.51 - $104.43 $16,960 - $25,480	-244 Reduced 63.38%	141 $14,000
Q3 2023 Nov 06, 2023	BUY	$96.41 - $126.61 $192 - $253	2 Added 0.52%	385 $39,000
Q2 2023 Jul 17, 2023	BUY	$118.5 - $160.53 $118 - $160	1 Added 0.26%	383 $46,000
Q1 2023 Apr 18, 2023	BUY	$135.66 - $197.02 $1,356 - $1,970	10 Added 2.69%	382 $58,000
Q4 2022 Feb 06, 2023	SELL	$118.38 - $210.04 $34,330 - $60,911	-290 Reduced 43.81%	372 $66,000
Q3 2022 Oct 25, 2022	BUY	$118.07 - $194.18 $35,421 - $58,254	300 Added 82.87%	662 $78,000
Q2 2022 Aug 15, 2022	BUY	$117.13 - $176.59 $6,442 - $9,712	55 Added 17.92%	362 $51,000
Q1 2022 May 12, 2022	BUY	$126.46 - $235.05 $758 - $1,410	6 Added 1.99%	307 $53,000
Q4 2021 Feb 15, 2022	BUY	$225.82 - $368.51 $35,227 - $57,487	156 Added 107.59%	301 $76,000
Q3 2021 Nov 30, 2021	BUY	$221.9 - $484.47 $443 - $968	2 Added 1.4%	145 $56,000
Q2 2021 Aug 17, 2021	BUY	$129.91 - $234.98 $389 - $704	3 Added 2.14%	143 $34,000
Q4 2020 Mar 10, 2021	BUY	$65.74 - $169.86 $6,573 - $16,986	100 Added 250.0%	140 $15,000
Q2 2020 Aug 13, 2020	BUY	$29.67 - $80.0 $1,186 - $3,200	40 New	40 $3,000

Others Institutions Holding MRNA

# of Institutions

1,113

Shares Held

241M

Call Options Held

9.26M

Put Options Held

12.1M

View Full List

About Moderna, Inc.

Ticker MRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 391,200,000
Market Cap $25.7B
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...

More about MRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hm Payson & CO, based on Form 13F filings with the SEC.

News

Stay updated on Hm Payson & CO with notifications on news.

Account